Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities
Open Access
- 30 December 2022
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 640-645
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control StudyTransplantation Proceedings, 2021
- Bamlanivimab for treatment of COVID‐19 in solid organ transplant recipients: Early single‐center experienceClinical Transplantation, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control StudyTransplantation, 2021
- Is COVID-19 infection more severe in kidney transplant recipients?American Journal of Transplantation, 2020
- Responding to COVID-19 in an Uninsured Hispanic/Latino Community: Testing, Education and Telehealth at a Free Clinic in Providence.2020
- Call for Action: Racial Disparities in Clinical ResearchClinical Infectious Diseases, 2020
- Handling Time-dependent Variables: Antibiotics and Antibiotic ResistanceClinical Infectious Diseases, 2016
- Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetesBMJ, 2010